ArticleAbdominal radiology (New York)2026
Natural history of focal nodular hyperplasia on gadoxetic acid-enhanced MRI: a multicenter cohort study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the natural history and longitudinal imaging evolution of focal nodular hyperplasia (FNH) using gadoxetic acid-enhanced MRI (EOB-MRI) in a multicenter cohort.
methodsThis retrospective multicenter cohort study enrolled patients with FNH who underwent both baseline and follow-up EOB-MRI. Lesion evolution was assessed using three complementary metrics: absolute diameter change (threshold ≥ 0.5 cm), relative percentage change (threshold ≥ 10%), and annual diameter change (cm/year). Hepatobiliary phase (HBP) phenotype transitions from baseline to final follow-up were assessed using a predefined four-tier classification system (types A-D). Multilevel mixed-effects models were applied to evaluate associations between clinical variables and longitudinal changes in lesion size.
resultsA total of 93 patients with 128 FNH lesions were included. Over a median follow-up of 39.2 months (range: 12.1-84.8 months), the majority of lesions remained stable (78/128, 60.9%) or decreased in size (37/128, 28.9%), whereas a minority exhibited interval enlargement (13/128, 10.2%). Among enlarging lesions, longitudinal HBP phenotype transitions were observed, including four from type A to type C, two from type D to type C, and one from type B to type D. At final follow-up, the mean lesion diameter was modestly but significantly smaller than at baseline (3.15 ± 1.52 cm vs. 3.31 ± 1.33 cm; P = 0.014), corresponding to a mean relative change of -6.2% and a mean annual change of -0.05 cm/year. Multilevel mixed-effects models revealed no independent associations between lesion enlargement or continuous diameter changes and any of the evaluated clinical variables, including sex, age, baseline body mass index, hepatic steatosis, oral contraceptive use, pregnancy history, or follow-up duration (all P > 0.05).
conclusionLongitudinal EOB-MRI follow-up demonstrates that FNH exhibits a largely indolent natural history, with predominant lesion stability or spontaneous regression. Clinically significant enlargement is infrequent and shows no association with hormonal or other clinical factors. These findings support conservative management and indicate that routine imaging surveillance may be unnecessary in asymptomatic patients with typical imaging features.
Indexed as
Identifiers
41995818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.